Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
London Pharmaceuticals And Research Corporation has 3 pending office actions in the Biotechnology & Pharmaceuticals field. These 3 actions are distributed across 3 distinct examiners and 3 distinct art units. This 1:1:1 ratio between actions, examiners, and art units indicates a fragmented prosecution landscape for the 3 pending office actions. Practitioners should note that with 3 distinct examiners involved, no single individual dominates the portfolio's timeline.
IANNUZO, NATALIE NMN is the busiest examiner with 1 busiest examiner pending office action. Since there are 3 distinct examiners for only 3 pending office actions, each case is handled by a different official. The 3 distinct art units involved mean that each of the 3 pending office actions is being evaluated under the specific standards of a different pharmaceutical division. Practitioners should tailor their approach to the 3 distinct examiners to resolve the 3 pending office actions effectively. Successfully navigating the 3 distinct art units is essential for clearing the 3 pending office actions. The 1 busiest examiner pending case under IANNUZO, NATALIE NMN is one of the 3 pending office actions requiring attention.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| IANNUZO, NATALIE NMN | 1 | 12.2% | +71.4% |
| DEKARSKE, MADELINE MCGUIRE | 1 | 20.0% | +50.0% |
| ISMAIL, REHANA | 1 | 76.2% | +34.8% |
| SHIAO, YIH-HORNG | 1 | 72.6% | +75.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18007982 | CANNABINOID-HYALURONIC ACID BIOCONJUGATES | SHIAO, YIH-HORNG | 23d overdue |
| 18572696 | CANNABINOID-CONTAINING FORMULA FOR SKIN CARE | IANNUZO, NATALIE NMN | — |
| 18560206 | PSILOCYBIN AND PSILOCIN CONJUGATES FOR TREATMENT OF MENTAL ILLNESSES | DEKARSKE, MADELINE MCGUIRE | — |
| 18007935 | RIGID CANNABIDIOL ANALOGUES AS POTENT MODULATORS OF CANNABINOID RECEPTORS AND USES THEREOF | ISMAIL, REHANA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18007982 | CANNABINOID-HYALURONIC ACID BIOCONJUGATES | SHIAO, YIH-HORNG | 23d overdue |
| 18572696 | CANNABINOID-CONTAINING FORMULA FOR SKIN CARE | IANNUZO, NATALIE NMN | — |
| 18560206 | PSILOCYBIN AND PSILOCIN CONJUGATES FOR TREATMENT OF MENTAL ILLNESSES | DEKARSKE, MADELINE MCGUIRE | — |
| 18007935 | RIGID CANNABIDIOL ANALOGUES AS POTENT MODULATORS OF CANNABINOID RECEPTORS AND USES THEREOF | ISMAIL, REHANA | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| 1622 | 1 |
| 1625 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18572696 | CANNABINOID-CONTAINING FORMULA FOR SKIN CARE | IANNUZO, NATALIE NMN | 1653 | §102§103§112 | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18560206 | PSILOCYBIN AND PSILOCIN CONJUGATES FOR TREATMENT OF MENTAL ILLNESSES | DEKARSKE, MADELINE MCGUIRE | 1622 | §103§112 | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18007935 | RIGID CANNABIDIOL ANALOGUES AS POTENT MODULATORS OF CANNABINOID RECEPTORS AND USES THEREOF | ISMAIL, REHANA | 1625 | §101§102§112 | Non-Final OA | — | Pending | Dec 02, 2022 |
| 18007982 | CANNABINOID-HYALURONIC ACID BIOCONJUGATES | SHIAO, YIH-HORNG | 1691 | §102§103§112 | Final Rejection | 23d overdue | Pending | Dec 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLondon Pharmaceuticals And Research Corporation has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Natalie Nmn Iannuzo has the most, with 1 of London Pharmaceuticals And Research Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
